<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157491</url>
  </required_header>
  <id_info>
    <org_study_id>SINAL1618</org_study_id>
    <nct_id>NCT04157491</nct_id>
  </id_info>
  <brief_title>Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer</brief_title>
  <official_title>A Single-center, Single-arm, Phase II Trial to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Recurrent or Advanced Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the Efficacy and safety of Anti-PD-1 antibody
      combined With anlotinib in the treatment of recurrent or advanced endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>Objective tumor response was defined as the proportion of patients whose tumor volume has been reduced to a predetermined value and can be maintained for more than 4 weeks, ie ORR=CR+PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DoR)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>Duration of response was defined as the time when the tumor is first evaluated as CR or PR to the first assessment for PD or for any cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>Disease control rate was defined as the proportion of subjects with complete response (CR) or partial response (PR) or disease stabilization (SD) in the analyzed population according to the RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Objective Response(TTR)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>Time to objective response was defined as the time from the start of treatment to the first objective tumor remission (CR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>Progression-free survival was defined as the duration of time from study entry to time of progression, death, or the date of last contact, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS）</measure>
    <time_frame>Approximately 48 months.</time_frame>
    <description>Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 12 months</measure>
    <time_frame>Approximately 12 months.</time_frame>
    <description>Overall survival rate at 12 months was defined as the proportion of patients who were still alive in 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>anlotinib and anti PD-1 antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anlotinib and anti PD-1 antibody</intervention_name>
    <description>Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.</description>
    <arm_group_label>anlotinib and anti PD-1 antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years of age and female;

          2. Histologically confirmed diagnosis of endometrial cancer；

          3. Patients must have received at least 1 cycle of platinum-based chemotherapy；

               -  Patients with recurrent endometrial cancer that has failed at least one line of
                  platinum-based system chemotherapy

               -  Patients with newly diagnosed advanced endometrial cancer has persist lesion
                  after standard treatment with surgery and chemotherapy ± radiotherapy （at least
                  one line of platinum-based systemic chemotherapy）

          4. At least one measurable lesion according to RECIST1.1 on CT;

          5. ECOG performance status 0-2;

          6. Life expectancy ≥ 3 months;

          7. Adequate hepatic, renal, heart, and hematologic functions. Absolute Neutrophil
             Count(ANC) ≥ 1.5×109/L, Platelet (PLT) ≥ 70×109/L, Hemoglobin(HGB) ≥ 80 g/L, total
             bilirubin within 1.5×the upper limit of normal (ULN), and serum transaminase≤2.5×Upper
             Limit Of Normal(ULN), serum creatine ≤ 1.5 x Upper Limit Of Normal(ULN), creatinine
             clearance rate ≥50ml/min, International Normalized Ratio&lt;1.5 x Upper Limit Of
             Normal(ULN), Urinary protein≤（+）and Thyroid stimulating hormone≤ 1.5 x Upper Limit Of
             Normal(ULN).

          8. Signed and dated informed consent.

        Exclusion Criteria:

          1. Pathology confirmed with sarcoma components (including malignant mixed mullerian
             tumors, endometrial leiomyosarcoma, and endometrial stromal sarcoma);

          2. Exposured to any anti-tumor drugs within 4 weeks;

          3. Less than 4 weeks since the patient underwent any major surgery or expect a major
             surgery during trial;

          4. Radiation therapy within 21 days（Palliative radiotherapy for bone metastases within14
             days）;

          5. Exposured to any anti-PD1 antibody drugs；

          6. Any unresolved toxicity CTCAE &gt; Grade 1 from the prior chemoradiation
             therapy（Excluding hair loss and neurotoxicity）;

          7. Current or prior use of any immunosuppressive medication or systemic hormone
             therapy（which are not to exceed 10 mg/day of prednisone, or an equivalent
             corticosteroid Prednisone&gt;10mg/d）within 14 days before the first dose of anti-PD1
             antibody and Anlotinib；

          8. Any primary malignancy within 5 years (except for fully treated in situ malignant such
             as breast cancer, bladder cancer, cervical carcinoma in situ, cutaneous basal cell
             carcinoma or squamous cell carcinoma);

          9. History of psychiatric drugs abuse and not be abstinent, or dysphrenia；

         10. Central nervous system diseases, including uncontrollable epilepsy and symptomatic
             brain metastases;

         11. Digestive diseases that may affect drug absorption (such as atrophic gastritis)

         12. Active ulcers, intestinal perforation, intractable intestinal obstruction, and history
             of digestive tract perforation within 28 days prior to enrollment；

         13. Uncontrolled hypertension（blood pressure &gt;140/90 mmHg after adequate treatment）;

         14. Severe cardiovascular disease: unstable angina pectoris, myocardial infarction, grade
             III-IV cardiac insufficiency (NYHA standard), and peripheral vascular disease above 2
             degrees within 6 months prior to enrollment;

         15. Severe arrhythmia requiring drug control, QT interval &gt;470ms；

         16. Active hemorrhage or hemorrhage tendency.

         17. Within 6 months before the first treatment occurs artery / venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack (TIA),
             hematencephalon, cerebral infarction), deep vein thrombosis and pulmonary embolism,
             etc.

         18. Active infections such as HIV/AIDS or other serious infectious diseases

         19. Any active autoimmune disease or history of autoimmune disease (including but not
             limit to autoimmune hepatitis, interstitial pneumonia, hepatitis, enteritis,
             nephritis, hyperthyroidism, pituitary inflammation, vasculitis, uveitis) . Patients
             need receiving systemic hormonal therapy and/or immunosuppressive therapy (eg asthma
             requiring bronchodilators);

         20. Receipt of live attenuated vaccination within 30 days prior to study entry;

         21. Known to be allergic to any drug in the study;

         22. For women of child-bearing age, the pregnancy test results (serum or urine) within 7
             days before enrolment must be negative. They will take appropriate methods for
             contraception during the study.

         23. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jundong Li</last_name>
    <phone>+86-20-87343104</phone>
    <email>lijd@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jundong Li</last_name>
      <phone>+86-20-87343104</phone>
      <email>lijd@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jundong Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>anlotinib</keyword>
  <keyword>anti PD-1 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

